Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | CMO, Immuno-oncology | December 17, 2018 | December 19, 2018 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | EVP, Chief Development Officer | March 16, 2023 | March 20, 2023 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP Prod Dev & Med Aff & CMO | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date December 17, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2018-12-18 transaction · row 15
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
14 source rowsRow 2 · 2018-12-17 · Exercise / conversion · Acquired 9,859 · Balance 9,859 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The exercise price is represented in American Depositary Shares. Row 3 · 2018-12-17 · Sale · Disposed 900 · Balance 8,959 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.16 to $131.1599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 4 · 2018-12-17 · Sale · Disposed 2,700 · Balance 6,259 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.38 to $132.3799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 5 · 2018-12-17 · Sale · Disposed 1,700 · Balance 4,559 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.4199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 6 · 2018-12-17 · Sale · Disposed 1,005 · Balance 3,554 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.43 to $134.4299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 7 · 2018-12-17 · Sale · Disposed 778 · Balance 2,776 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.60 to $135.5999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 8 · 2018-12-17 · Sale · Disposed 2,296 · Balance 480 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $136.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 9 · 2018-12-17 · Sale · Disposed 480 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.65 to $137.6499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 10 · 2018-12-18 · Exercise / conversion · Acquired 10,141 · Balance 10,141 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The exercise price is represented in American Depositary Shares. Row 11 · 2018-12-18 · Sale · Disposed 1,631 · Balance 8,510 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.01 to $132.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 12 · 2018-12-18 · Sale · Disposed 1,897 · Balance 6,613 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.22 to $133.2199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 13 · 2018-12-18 · Sale · Disposed 2,402 · Balance 4,211 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.32 to $134.3199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 14 · 2018-12-18 · Sale · Disposed 3,600 · Balance 611 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.37 to $135.3699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 15 · 2018-12-18 · Sale · Disposed 611 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.40 to $136.3999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2026-08-21 | Direct | 951,833 |
Reported balance
After 2018-12-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-12-17 · Exercise / conversion · Disposed 128,167 · Balance 951,833 F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2026-08-21 | Direct | 820,000 |
Reported balance
After 2018-12-18 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-12-18 · Exercise / conversion · Disposed 131,833 · Balance 820,000 F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 194,569 |
Reported balance
Holding disclosure · report date 2018-12-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 194,569 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The exercise price is represented in American Depositary Shares.
F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.16 to $131.1599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.38 to $132.3799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.4199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.43 to $134.4299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.60 to $135.5999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $136.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.65 to $137.6499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.01 to $132.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.22 to $133.2199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.32 to $134.3199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.37 to $135.3699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.40 to $136.3999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.
CytomX Therapeutics, Inc.
Report date March 16, 2023 · Filed March 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,433 |
Reported balance
After 2023-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-16 · Sale · Disposed 4,257 · Balance 58,433 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units. F2: Includes 30,000 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
F2: Includes 30,000 restricted stock units.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 465,393 |
Last balance in matching sequence
After 2025-05-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 8,303 · Balance 498,169 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024. F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-16 · Exercise / conversion · Acquired 40,000 · Balance 538,169 F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 3 · 2025-05-16 · Sale · Disposed 72,776 · Balance 465,393 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.75 · Expires 2030-08-23 | Direct | 120,000 |
Reported balance
After 2025-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-16 · Exercise / conversion · Disposed 40,000 · Balance 120,000 F4: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024.
F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 322 | $123.75 | $39,846.73 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 14 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.50 to $124.4999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,046 | $122.55 | $250,732.80 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 13 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.21 to $123.2099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,898 | $121.71 | $352,703.70 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 12 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.18 to $122.1799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,100 | $120.63 | $253,325.10 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 11 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,366 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.14 to $121.1399, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,725 | $119.27 | $205,739.72 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 10 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,466 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.01 to $120.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,031 | $118.64 | $478,217.69 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 9 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,191 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.01 to $119.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 13,222 | $29.10 | $384,760.20 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 8 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The exercise price is represented in American Depositary Shares. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 191,243 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · derivative · entry 25 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,408,757 Underlying: Ordinary Shares · 191,243 shares Expires 2026-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F25 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $127.61 | $25,521.50 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 7 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.50 to $128.4999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,673 | $126.72 | $972,320.26 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 6 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4616 to $127.4615, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,949 | $126.08 | $497,879.26 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 5 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,873 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.45 to $126.4499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,423 | $124.48 | $301,605.11 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 4 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,822 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.18 to $125.1799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 466 | $122.86 | $57,251.13 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 3 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,245 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.34 to $123.3399, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 14,711 | $29.10 | $428,090.10 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The exercise price is represented in American Depositary Shares. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 20:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 961 | $170.46 | $163,815.33 |
DisclosureSEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 4 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.30 to $170.87, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 20:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,400 | $169.75 | $237,656.02 |
DisclosureSEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 3 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 961 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.27 to $170.19, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 20:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,300 | $168.94 | $388,565.22 |
DisclosureSEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,361 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.25 to $169.24, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 20:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,108 | $167.54 | $185,629.89 |
DisclosureSEC source: 0001179110-18-010878 · edgar.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,661 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.05 to $167.77, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 310,180 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001179110-18-009112 · edgar.xml · derivative · entry 2 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,180 Underlying: Ordinary Shares · 310,180 shares Expires 2028-06-25 F2 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F3 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. F2 · derivative.underlying_shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · balance_after: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 44,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009112 · edgar.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,566 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,201 | $83.31 | $100,054.23 |
DisclosureSEC source: 0001179110-17-014170 · edgar.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.13 to $84.04, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| November 13, 2017 Filed Nov 16, 2017 01:11 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,400 | $82.79 | $198,692.88 |
DisclosureSEC source: 0001179110-17-014170 · edgar.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.12 to $83.11, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| August 22, 2017 Filed Aug 24, 2017 20:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Tax withholdingOrdinary Shares | 28,185 | $5.39 | $151,829.78 |
DisclosureSEC source: 0001179110-17-011812 · edgar.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,815 F1 · shares: Represents shares withheld to settle tax liability in connection with the vesting of a restricted share award that was previously granted on August 22, 2016. The share withholding was approved by a committee of non-employee directors in accordance with requirements of Rule 16b-3. F2 · price: Calculated based off the closing price of the Company's American Depositary Shares ("ADSs") on the date thereof. Each ADS represents 13 Ordinary Shares. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 23:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 1,016,178 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001179110-17-009798 · edgar.xml · derivative · entry 1 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,178 Underlying: Ordinary shares · 1,016,178 shares Expires 2027-06-26 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F2 · derivative.exercise_date: The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter. Unvested options are subject to accelerated vesting upon certain termination events following a change in control. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our American Depositary Shares ("ADSs") on the date of grant, as each ADS represents 13 ordinary shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.